drugset
drugset / Trial / NCT04949269

A Study to Evaluate the Drug Levels of Deucravacitinib From Tablets After Oral Administration in Healthy Participants

NCT04949269 ↗

Phase 1 Completed 61 enrolled Bristol-Myers Squibb
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to assess the drug levels of deucravacitinib after oral administration in healthy participants.

Timeline

Start
2021-07-20
Primary completion
2022-01-03
Completion
2022-01-03

Drugs

EvaluationDrugModalityDoseRoute
Subject CRAVACITINIB Small molecule — Oral
Background Famotidine Other / unclassified — —

Indications

No indication recorded.